

PATENT
Docket No. 313332000101

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on February 1, 2001.

Marieta Luke
Marieta Luke

1c987 U.S. PTO
09/774681
02/01/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Linda A. SHERMAN et al.

Serial No.: To be assigned
(Divisional of 08/812,393)

Filing Date: February 1, 2001

For: RECOMBINANT CONSTRUCTS
ENCODING T CELL RECEPTORS
SPECIFIC FOR HUMAN HLA-
RESTRICTED TUMOR ANTIGENS

Examiner: To be assigned

Group Art Unit: To be assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 08/812,393 filed March 5, 1997, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted with the filing of a new U.S. patent application. No fee is required.


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 31333-2000100. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 1, 2001

Respectfully submitted,

By: 
Thomas G. Wiseman
Registration No. 35,046

Morrison & Foerster^{LLP}
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888
Telephone: (202) 778-1678
Facsimile: (202) 887-0763

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 313332000101	Application Number to be assigned
	Applicant Linda A. SHERMAN et al.	
	Filing Date February 1, 2001	Group Art Unit to be assigned

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	1.	Hock, R.A., <i>et al.</i> , "Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells," <i>Nature</i> (1996) 320:275-277
	2.	LaFace, D.M., <i>et al.</i> , "Human CD8 transgene regulation of HLA recognition by murine T cells," <i>J Exp Med</i> (1995) 182:1315-1325
	3.	Le, A.T., <i>et al.</i> , "Cytotoxic T cell responses in HLA-A2.1 transgenic mice," <i>J Immunol</i> (1989) 142(4):1366-1371
	4.	Lustgarten, J., <i>et al.</i> , "Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8," <i>Human Immunology</i> (1997) 52(2):109-118
	5.	Man, S., <i>et al.</i> , "Diversity and dominance among TCR recognizing HLA-A2.1 ⁺ influenza matrix peptide in human MHC Class I transgenic mice," <i>J Immunol</i> (1994) 153:4458-4467
	6.	Moller, P., <i>et al.</i> , "The role of surface HLA-A,B,C molecule in tumour immunity," <i>Cancer Surveys</i> (1992) 13:101-127
	7.	Ressing, M.E., <i>et al.</i> , "Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A *0201-binding peptides," <i>J Immunol</i> (1995) 154:5934-5943
	8.	Theobald, M., <i>et al.</i> , "Targeting p53 as a general tumor antigen," <i>Proc Natl Acad Sci USA</i> (1995) 92:11993-11997
	9.	Wentworth, P.A., <i>et al.</i> , "Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice," <i>Eur J Immunol</i> (1996) 26:97-101
	10.	Zisman, E., <i>et al.</i> , "Dichotomy between the T and the B cell epitopes of the synthetic peptide (T,G)-A--L*," <i>Eur J Immunol</i> (1994) 24:2497-2505

EXAMINER: (examiner)

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 313332000101

Application Number to be assigned

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Linda A. SHERMAN et al.

Filing Date February 1, 2001

Group Art Unit to be assigned

- | | |
|-----|---|
| 11. | Greenberg, P.D. <i>Adv Immunol</i> (1991) 49:281-355 |
| 12. | Yanuck, M. <i>et al. Cancer Res</i> (1993) 53:3257-3261 |
| 13. | Houbiers, J.G.A. <i>et al. Eur J Immunol</i> (1993) 23:2072-2077 |
| 14. | Peoples, G.E. <i>et al. Proc Natl Acad Sci USA</i> (1995) 92:432-436 |
| 15. | Skipper, J. <i>et al. J Exp Med</i> (1993) 177:1493-1498 |
| 16. | Schwartz, R.H. <i>Cell</i> (1989) 57:1073-1081 |
| 17. | Browning, M.J. <i>et al. Curr Opin Immunol</i> (1992) 4:613-618 |
| 18. | Mizoguchi, H. <i>et al. Science</i> (1992) 258:1795-1798 |
| 19. | Vitiello, A. <i>et al. J Exp Med</i> (1991) 173:1007-1015 |
| 20. | Wegener, A.M.K. <i>et al. Cell</i> (1992) 68:83 |
| 21. | Engel, I. <i>et al. Science</i> (1992) 256:1318 |
| 22. | Irving, B.A. <i>et al. Cell</i> (1991) 64:891 |
| 23. | Chung, S. <i>et al. Proc Natl Acad Sci USA</i> (1994) 91:12654-12658 |
| 24. | Wall Theriogenology, Vol. 45, pgs.57-68 (1996) |
| 25. | Ebert et al., <i>Mol. Endocrinology</i> Vol. 2, pgs. 277-283 (1988) |
| 26. | Overbeek "Factors affecting transgenic animal production" <i>Transgenic animal technology</i> , pgs. 96-98 (1994) |
| 27. | Salazar-Onfray et al., <i>Cancer Res.</i> , Vol. 57, pgs. 4348-4355 (10-1997) |
| 28. | Fetsch et al., <i>Cancer Cytopathology</i> , Vol. 87, pgs. 37-42 (2-1999) |
| 29. | Cole et al., <i>FASEB Journal</i> , Vol. 9, pgs. A801, abstract 4638 (4-1995) |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.